Cholesterol ( DrugBank: Cholesterol )

6 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
8	ハンチントン病	1
19	ライソゾーム病	26
90	網膜色素変性症	1
160	先天性魚鱗癬	2
222	一次性ネフローゼ症候群	2
310	先天異常症候群	7

8. ハンチントン病

臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-003052-16-FR (EUCTR)	20/07/2022	08/12/2021	Phase I/II Safety and Tolerability Study of striatal administration of BV-101 in adult subjects with ...	An Open-Label Phase I/II Dose Finding Study to evaluate the Safety, Tolerability, and Preliminary Ef ...	Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's ...	Product Name: AAVrh10.CAG.hCYP46A1 Product Code: BV-101 INN or Proposed INN: AAVrh10.CAG.hCYP46A1 Other ...	Brainvectis	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	18	Phase 1;Phase 2	United States;France

First Previous1Next Last

19. ライソゾーム病

臨床試験数 : 899 / 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182

diseases per page:

Showing 1 to 10 of 26 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02912793 (ClinicalTrials.gov)	March 20, 2017	19/8/2016	Safety and Efficacy of Intravenous Trappsol Cyclo (HPBCD) in Niemann-Pick Type C Patients	A Phase I/II Study to Evaluate the Safety and PK of iv Trappsol Cyclo (HP-ß-CD) in Patients With Nie ...	Niemann-Pick Disease, Type C1	Drug: Hydroxypropyl-beta-cyclodextrin	Cyclo Therapeutics, Inc.	NULL	Completed	2 Years	N/A	All	12	Phase 1/Phase 2	Israel;Sweden;United Kingdom
2	EUCTR2015-005761-23-SE (EUCTR)	19/01/2017	09/09/2016	A Phase I/II study to evaluate Trappsol Cyclo (hydroxypropyl-ß-cyclodextrin) in patients with Nieman ...	A Phase I/II study to evaluate the safety and pharmacokinetics of intravenous Trappsol Cyclo (HP-ß-C ...	Niemann-Pick disease type C MedDRA version: 20.0;Level: PT;Classification code 10029403;Term: Nieman ...	Product Name: Trappsol Cyclo INN or Proposed INN: hydroxypropyl-beta-cyclodextrin Other descriptive na ...	Cyclo Therapeutics, Inc.	NULL	Not Recruiting			Female: yes Male: yes	11	Phase 1;Phase 2	United Kingdom;Italy;Sweden
3	EUCTR2015-005761-23-GB (EUCTR)	26/09/2016	03/08/2016	A Phase I/II study to evaluate Trappsol Cyclo (hydroxypropyl-ß-cyclodextrin) in patients with Nieman ...	A Phase I/II study to evaluate the safety and pharmacokinetics of intravenous Trappsol Cyclo (HP-ß-C ...	Niemann-Pick disease type C MedDRA version: 20.0;Level: PT;Classification code 10029403;Term: Nieman ...	Product Name: Trappsol Cyclo INN or Proposed INN: hydroxypropyl-beta-cyclodextrin Other descriptive na ...	CTD Holdings, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	12	Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ...	Italy;United Kingdom;Sweden
4	EUCTR2014-000533-22-FI (EUCTR)	23/06/2015	05/06/2015	Study of sebelipase alfa in young children with Lysosomal Acid Lipase Deficiency (LALD).	A Phase 2, Open Label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmac ...	Lysosomal Acid Lipase Deficiency (LALD) MedDRA version: 19.1;Level: HLT;Classification code 10024579 ...	Product Name: Sebelipase Alfa Product Code: SBC-102 INN or Proposed INN: sebelipase alfa Other descript ...	Alexion Pharmaceuticals Inc	NULL	Not Recruiting			Female: yes Male: yes	10	Phase 2	United States;Finland;Italy;United Kingdom
5	EUCTR2011-004287-30-NL (EUCTR)	29/05/2015	01/04/2015	Study of sebelipase alfa in a broad population of patients with Lysosomal Acid Lipase Deficiency (LA ...	A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with Lysosomal Acid Lipase Deficiency ...	Lysosomal Acid Lipase Deficiency (LALD) MedDRA version: 19.1;Level: HLT;Classification code 10024579 ...	Product Name: Sebelipase Alfa Product Code: SBC-102 INN or Proposed INN: sebelipase alfa Other descript ...	Alexion Pharmaceuticals Inc	NULL	Not Recruiting			Female: yes Male: yes	30	Phase 2	United States;Spain;Turkey;Russian Federation;United Kingdom;Italy;Mexico;Canada;Belgium;Brazil;Croa ...
6	EUCTR2011-002750-31-CZ (EUCTR)	16/02/2015	22/03/2013	A study of SBC-102 (enzyme replacement therapy) in patients with lysosomal acid lipase deficiency	A multicenter, randomized, placebo-controlled study of SBC-102 in patients with lysosomal acid lipas ...	Lysosomal Acid Lipase Deficiency MedDRA version: 20.0;Level: HLT;Classification code 10024579;Term: ...	Trade Name: KANUMA Product Name: sebelipase alfa Product Code: SBC-102 INN or Proposed INN: NA Other des ...	Alexion Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	55	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	United States;Taiwan;Greece;Spain;Ukraine;Russian Federation;Chile;Israel;Italy;France;Cyprus;Austra ...
7	EUCTR2011-004287-30-GB (EUCTR)	19/01/2015	11/04/2014	Study of sebelipase alfa in a broad population of patients with Lysosomal Acid Lipase Deficiency (LA ...	A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with Lysosomal Acid Lipase Deficiency ...	Lysosomal Acid Lipase Deficiency (LALD) MedDRA version: 18.1;Level: HLT;Classification code 10024579 ...	Product Name: Sebelipase Alfa Product Code: SBC-102 INN or Proposed INN: sebelipase alfa Other descript ...	Alexion Pharmaceuticals Inc	NULL	Not Recruiting			Female: yes Male: yes	20	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	United States;Spain;Turkey;Russian Federation;United Kingdom;Italy;Mexico;Canada;Belgium;Poland;Braz ...
8	EUCTR2011-004287-30-IT (EUCTR)	18/09/2014	18/04/2014	Study of sebelipase alfa in a broad population of patients with Lysosomal Acid Lipase Deficiency (LA ...	A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with Lysosomal Acid Lipase Deficiency ...	Lysosomal Acid Lipase Deficiency (LALD) MedDRA version: 16.1;Level: HLT;Classification code 10024579 ...	Product Name: Sebelipase Alfa Product Code: SBC-102 INN or Proposed INN: sebelipase alfa Other descript ...	Synageva BioPharma Corp.	NULL	Not Recruiting			Female: yes Male: yes	20	Phase 2	United States;Spain;Turkey;Russian Federation;United Kingdom;Italy;Mexico;Canada;Belgium;Brazil;Pola ...
9	EUCTR2014-000533-22-IT (EUCTR)	18/09/2014	22/07/2014	Study of sebelipase alfa in young children with Lysosomal Acid Lipase Deficiency (LALD).	A Phase 2, Open Label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmac ...	Lysosomal Acid Lipase Deficiency (LALD) MedDRA version: 17.0;Level: HLT;Classification code 10024579 ...	Product Name: Sebelipase Alfa Product Code: SBC-102 INN or Proposed INN: sebelipase alfa Other descript ...	Synageva BioPharma Corp.	NULL	Not Recruiting			Female: yes Male: yes	10	Phase 2	United States;Finland;United Kingdom;Italy
10	EUCTR2011-004287-30-DE (EUCTR)	12/08/2014	13/05/2014	Study of sebelipase alfa in a broad population of patients with Lysosomal Acid Lipase Deficiency (LA ...	A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with Lysosomal Acid Lipase Deficiency ...	Lysosomal Acid Lipase Deficiency (LALD) MedDRA version: 19.1;Level: HLT;Classification code 10024579 ...	Product Name: Sebelipase Alfa Product Code: SBC-102 INN or Proposed INN: sebelipase alfa Other descript ...	Alexion Pharmaceuitcals Inc	NULL	Not Recruiting			Female: yes Male: yes	30	Phase 2	United States;Spain;Turkey;Russian Federation;United Kingdom;Italy;Mexico;Canada;Belgium;Brazil;Croa ...

First Previous1 2 3Next Last

先頭へ

90. 網膜色素変性症

臨床試験数 : 147 / 薬物数 : 176 - (DrugBank : 43) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 110

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01773278 (ClinicalTrials.gov)	December 2008	3/12/2012	Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)	Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)	Smith-Lemli-Opitz Syndrome;Cone-Rod Dystrophy;Hearing Loss	Drug: Antioxidants;Drug: Cholesterol	University of Colorado, Denver	NULL	Recruiting	N/A	65 Years	All	100	Phase 2	United States

First Previous1Next Last

160. 先天性魚鱗癬

臨床試験数 : 42 / 薬物数 : 71 - (DrugBank : 21) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 112

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs031180409	25/12/2013	22/03/2019	Treatment of the genetic defect of cholesterol biosynthetic pathway.	Treatment of the genetic defect of cholesterolbiosynthetic pathway by the topical application of sta ...	CHILD syndrome, Conradi syndrome, porokeratosis, atopic dermatitis, psoriasis, seborrheic dermatitis ...	To patients, 1% atorvastatin/ 2% cholesterollotion and/or 1% atorvastatin/ 2% cholesterolointment, a ...	Kubo Akiharu	NULL	Complete	Not applicable	Not applicable	Both	158	Phase 2	Japan
2	NCT01110642 (ClinicalTrials.gov)	July 2011	22/4/2010	Novel Treatment for Syndromic Ichthyoses	Open-label, Pilot Study to Assess Cholesterol-Lovastatin Solution in the Treatment of Syndromic Icht ...	Syndromic Ichthyoses;CHILD Syndrome;Smith Lemli Opitz Syndrome;Conradi Syndrome	Drug: Lovastatin	Northwestern University	NULL	Withdrawn	1 Year	N/A	Both	0	Phase 2	United States

First Previous1Next Last

222. 一次性ネフローゼ症候群

臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2200058162	2022-05-01	2022-03-31	Efficacy of CRS model combining serum anti-PLA2R antibody and GRS score for diagnosis and prognosis ...	Efficacy of CRS model combining serum anti-PLA2R antibody and GRS score for diagnosis and prognosis ...	Idiopathic membranous nephropathy	Gold Standard:Chronic kidney disease was first diagnosed according to the presence of edema, protein ...	Yuebei People’s Hospital	NULL	Pending	18		Both	Target condition:50;Difficult condition:50		China
2	ChiCTR-TQR-12002602	2009-10-09	2012-10-16	The Effects of an Combinedative Treatment of with Prednisone plus and Fluvastatin on the Levels of C ...	The Effects of an Combinedative Treatment of with Prednisone plus and Fluvastatin on the Levels of C ...	Minimal change nephrotic syndrome in children	Treatment:prednisone 1~2 mg/kg/day+Fluvastatin Sodium Capsule;Control:prednisone 1~2 mg/kg/day;	Treatment center of kidney disease, 281th hospital of PLA	NULL	Completed	4	12	Both	Treatment:30;Control:30;	I (Phase 1 study)	China

First Previous1Next Last

310. 先天異常症候群

臨床試験数 : 11 / 薬物数 : 20 - (DrugBank : 10) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 7

diseases per page:

Showing 1 to 7 of 7 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01434745 (ClinicalTrials.gov)	September 2011	7/9/2011	SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation	Smith-Lemli Opitz Syndrome: A Clinical Investigation of the Effect of Simvastatin in Patients Receiv ...	Smith-Lemli-Opitz Syndrome	Drug: Simvastatin;Dietary Supplement: Lactose	Oregon Health and Science University	National Heart, Lung, and Blood Institute (NHLBI)	Terminated	1 Year	89 Years	All	1	N/A	United States
2	NCT01110642 (ClinicalTrials.gov)	July 2011	22/4/2010	Novel Treatment for Syndromic Ichthyoses	Open-label, Pilot Study to Assess Cholesterol-Lovastatin Solution in the Treatment of Syndromic Icht ...	Syndromic Ichthyoses;CHILD Syndrome;Smith Lemli Opitz Syndrome;Conradi Syndrome	Drug: Lovastatin	Northwestern University	NULL	Withdrawn	1 Year	N/A	Both	0	Phase 2	United States
3	NCT01356420 (ClinicalTrials.gov)	January 2011	11/5/2011	Sterol and Isoprenoid Disease Research Consortium: Smith-Lemli-Opitz Syndrome	Smith-Lemli-Opitz Syndrome: A Longitudinal Clinical Study of Patients Receiving CholesterolSupplemen ...	Smith-Lemli-Opitz Syndrome	Dietary Supplement: Cholesterol supplementation	Oregon Health and Science University	NULL	Terminated	N/A	85 Years	All	21	N/A	United States
4	NCT01773278 (ClinicalTrials.gov)	December 2008	3/12/2012	Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)	Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)	Smith-Lemli-Opitz Syndrome;Cone-Rod Dystrophy;Hearing Loss	Drug: Antioxidants;Drug: Cholesterol	University of Colorado, Denver	NULL	Recruiting	N/A	65 Years	All	100	Phase 2	United States
5	NCT00114634 (ClinicalTrials.gov)	June 2005	15/6/2005	Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome	Short-Term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome	Smith-Lemli-Opitz Syndrome	Dietary Supplement: Egg yolk preparation with cholesterol;Dietary Supplement: Egg substitute, withou ...	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	NULL	Completed	4 Years	17 Years	All	13	Phase 2	United States
6	NCT00001721 (ClinicalTrials.gov)	September 13, 1998	3/11/1999	Study of Smith-Lemli-Opitz Syndrome	Clinical and Basic Investigations Into Smith-Lemli-Opitz Syndrome	Smith-Lemli-Opitz Syndrome	Drug: Cholesterol Suspension;Drug: CRH;Drug: Cholesterol	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	NULL	Completed	N/A	N/A	All	130		United States
7	NCT00272844 (ClinicalTrials.gov)	January 1998	4/1/2006	Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome	Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome	Smith-Lemli-Opitz Syndrome	Drug: crystalline cholesterol oil-based suspension	Boston Children’s Hospital	NULL	Completed	N/A	N/A	All	23	Phase 1/Phase 2	United States

First Previous1Next Last

先頭へ